Viridian Therapeutics, Inc. (NASDAQ:VRDN) to Post FY2022 Earnings of ($3.65) Per Share, Oppenheimer Forecasts

Viridian Therapeutics, Inc. (NASDAQ:VRDNGet Rating) – Investment analysts at Oppenheimer dropped their FY2022 earnings per share estimates for Viridian Therapeutics in a research report issued to clients and investors on Tuesday, November 15th. Oppenheimer analyst L. Gershell now forecasts that the company will earn ($3.65) per share for the year, down from their prior forecast of ($3.29). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.49) per share. Oppenheimer also issued estimates for Viridian Therapeutics’ Q4 2022 earnings at ($0.81) EPS, Q1 2023 earnings at ($0.77) EPS, Q2 2023 earnings at ($0.79) EPS, Q3 2023 earnings at ($0.81) EPS, Q4 2023 earnings at ($0.78) EPS, FY2023 earnings at ($3.15) EPS, FY2024 earnings at ($2.65) EPS, FY2025 earnings at ($2.31) EPS and FY2026 earnings at ($0.85) EPS.

A number of other research analysts have also recently commented on the company. B. Riley upped their target price on Viridian Therapeutics from $25.00 to $40.00 in a research note on Tuesday, August 16th. JMP Securities cut their target price on Viridian Therapeutics from $47.00 to $46.00 and set a “market outperform” rating on the stock in a research note on Tuesday. LADENBURG THALM/SH SH upped their target price on Viridian Therapeutics from $33.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 16th. Wedbush upped their target price on Viridian Therapeutics to $43.00 in a research note on Thursday. Finally, SVB Leerink increased their price objective on Viridian Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, August 15th.

Viridian Therapeutics Trading Down 1.5 %

VRDN opened at $22.55 on Friday. The stock has a market cap of $641.86 million, a price-to-earnings ratio of -5.40 and a beta of 0.84. The stock’s 50 day moving average price is $20.51 and its 200-day moving average price is $16.55. Viridian Therapeutics has a one year low of $9.47 and a one year high of $26.22. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.77 and a current ratio of 17.35.

Insider Buying and Selling

In other Viridian Therapeutics news, General Counsel Lara Meisner sold 8,125 shares of the company’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $22.05, for a total transaction of $179,156.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.48% of the stock is owned by insiders.

Institutional Trading of Viridian Therapeutics

A number of hedge funds have recently bought and sold shares of VRDN. Endurant Capital Management LP lifted its holdings in shares of Viridian Therapeutics by 23.4% during the 1st quarter. Endurant Capital Management LP now owns 83,217 shares of the company’s stock valued at $1,539,000 after purchasing an additional 15,767 shares during the last quarter. Paradigm Biocapital Advisors LP lifted its holdings in shares of Viridian Therapeutics by 3.9% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 1,256,051 shares of the company’s stock valued at $23,224,000 after purchasing an additional 47,000 shares during the last quarter. Maven Securities LTD lifted its holdings in shares of Viridian Therapeutics by 25.2% during the 1st quarter. Maven Securities LTD now owns 27,486 shares of the company’s stock valued at $508,000 after purchasing an additional 5,535 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of Viridian Therapeutics by 47.3% during the 1st quarter. Walleye Capital LLC now owns 162,281 shares of the company’s stock valued at $3,001,000 after purchasing an additional 52,106 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Viridian Therapeutics during the 1st quarter valued at $32,164,000.

Viridian Therapeutics Company Profile

(Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

Recommended Stories

Earnings History and Estimates for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.